Abstract
The alpha-glucosidase inhibitor acarbose is administered to control blood glucose levels in type 2 diabetic patients and, in several countries, in those with impaired glucose tolerance. The efficacy and safety of the drug has been well established in these patient populations. Acarbose shows no weakening of efficacy in long-term diabetes treatment, reduces the development of type 2 diabetes in those with impaired glucose tolerance, and also appears to reduce the risk of cardiovascular disease. The underlying mechanisms of its effect on the risk of developing macrovascular complications have still to be elucidated. The mode of action of acarbose, which precedes all other metabolic processes involved in blood glucose regulation, inhibits high increases in postprandial blood glucose. Due to this early mode of action, acarbose also modifies insulin and proinsulin secretion which are both involved in ß-cell dysfunction and insulin resistance and may be independent risk factors for cardiovascular mortality. Based on the literature available the present state of knowledge on insulin and proinsulin as risk factors for cardiovascular mortality is reviewed as well as the effect of acarbose on the regulation of the ß-cells as monotherapy and in combination regimens. Possible associated interactions with the cardiovascular system are identified.
Keywords: Acarbose, Proinsulin, Serum insulin, ß-cell function, Cardiovascular disease
Current Diabetes Reviews
Title: Effects of Acarbose on Proinsulin and Insulin Secretion and their Potential Significance for the Intermediary Metabolism and Cardiovascular System
Volume: 5 Issue: 3
Author(s): Christoph Rosak and Gabriele Mertes
Affiliation:
Keywords: Acarbose, Proinsulin, Serum insulin, ß-cell function, Cardiovascular disease
Abstract: The alpha-glucosidase inhibitor acarbose is administered to control blood glucose levels in type 2 diabetic patients and, in several countries, in those with impaired glucose tolerance. The efficacy and safety of the drug has been well established in these patient populations. Acarbose shows no weakening of efficacy in long-term diabetes treatment, reduces the development of type 2 diabetes in those with impaired glucose tolerance, and also appears to reduce the risk of cardiovascular disease. The underlying mechanisms of its effect on the risk of developing macrovascular complications have still to be elucidated. The mode of action of acarbose, which precedes all other metabolic processes involved in blood glucose regulation, inhibits high increases in postprandial blood glucose. Due to this early mode of action, acarbose also modifies insulin and proinsulin secretion which are both involved in ß-cell dysfunction and insulin resistance and may be independent risk factors for cardiovascular mortality. Based on the literature available the present state of knowledge on insulin and proinsulin as risk factors for cardiovascular mortality is reviewed as well as the effect of acarbose on the regulation of the ß-cells as monotherapy and in combination regimens. Possible associated interactions with the cardiovascular system are identified.
Export Options
About this article
Cite this article as:
Rosak Christoph and Mertes Gabriele, Effects of Acarbose on Proinsulin and Insulin Secretion and their Potential Significance for the Intermediary Metabolism and Cardiovascular System, Current Diabetes Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339909788920910
DOI https://dx.doi.org/10.2174/157339909788920910 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ageing Mechanisms and Associated Lipid Changes
Current Vascular Pharmacology Pharmaceutical and Biomedical Analysis of Terpene Constituents in Salvia miltiorrhiza
Current Pharmaceutical Analysis Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Cerebral Amyloid Angiopathy-related Intracerebral Hemorrhage Score For Predicting Outcome
Current Neurovascular Research A Micro-Aggregation Algorithm Based on Density Partition Method for Anonymizing Biomedical Data
Current Bioinformatics Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry MicroRNA-21 as Therapeutic Target in Cancer and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Infectious Disorders - Drug Targets Pharmacological and Clinical Applications of Natriuretic Peptides: Accepted Knowledges or Changing Views?
Current Pharmaceutical Analysis Development of Improved Factor VIII Molecules and New Gene Transfer Approaches for Hemophilia A
Current Gene Therapy Prediction of Degeneration of Native and Bioprosthetic Aortic Valves:Issue-Related Particularities of Diabetes Mellitus
Infectious Disorders - Drug Targets Imaging Neuroinflammation in Ischemic Stroke and in the Atherosclerotic Vascular Disease
Current Vascular Pharmacology Immunologic Considerations in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Low Lymphocyte Count and Cardiovascular Diseases
Current Medicinal Chemistry Obstructive Sleep Apnea and Type 2 Diabetes: Dual Interaction
Current Respiratory Medicine Reviews Heterocyclic Chalcone Analogues as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Ethiopathogenesis, Diagnosis and Prevention of Vascular Calcification in End Stage Renal Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction
Current Drug Safety A New Risk Chart of Acute Myocardial Infarction in Men by an Innovative Algorithm: A Pilot Study
Current Pharmacogenomics and Personalized Medicine Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets